Mather Group LLC. Sells 95,443 Shares of Johnson & Johnson (NYSE:JNJ)

Mather Group LLC. lessened its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 72.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 36,401 shares of the company's stock after selling 95,443 shares during the period. Mather Group LLC.'s holdings in Johnson & Johnson were worth $6,037,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson during the 4th quarter worth about $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson during the 4th quarter worth about $29,000. Conquis Financial LLC acquired a new position in Johnson & Johnson during the 4th quarter worth about $33,000. Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson during the 4th quarter worth about $36,000. Finally, Highline Wealth Partners LLC lifted its position in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after buying an additional 86 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.2%

Shares of NYSE:JNJ traded up $0.34 during mid-day trading on Friday, reaching $155.90. The stock had a trading volume of 3,482,521 shares, compared to its average volume of 8,047,072. The firm has a market cap of $375.11 billion, a PE ratio of 17.34, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The firm has a 50 day simple moving average of $153.68 and a two-hundred day simple moving average of $154.03. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.34%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research reports. Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Bank of America cut their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. Royal Bank Of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their target price for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.